Market participants should monitor for future KLRA IPO activity, as Bain Capital's stake is structured to automatically convert to common stock upon IPO. This filing confirms institutional backing but does not indicate immediate trading implications.
Price Chart
Executive Summary
Bain Capital Life Sciences has filed an initial Form 3 disclosing beneficial ownership of 21,020,768 shares of Kailera Therapeutics, Inc. (KLRA), consisting of 16,875,000 shares of Series A-1 Preferred Stock and 4,145,768 shares of Common Stock. The filing reflects a new passive investment position by a major life sciences private equity firm ahead of a potential IPO.
Key Facts
- Bain Capital Life Sciences entities filed initial Form 3 for Kailera Therapeutics, Inc. (KLRA)
- Total beneficial ownership: 21,020,768 shares (16,875,000 Series A-1 Preferred, 4,145,768 Common)
- Each share of Series A-1 and Series B Preferred Stock is convertible into Common Stock on a 1:1 basis
- Automatic conversion of preferred shares upon closing of KLRA's initial public offering
- Bain Capital Life Sciences Investors, LLC is the ultimate manager of the investment vehicle holding the shares
- All reporting entities disclaim beneficial ownership except to the extent of their pecuniary interest
Financial Impact
Undisclosed value; position represents a significant passive stake in a pre-IPO biotech company
Risk Factors
- KLRA remains pre-revenue with no public financials; investment is highly speculative
- No guarantee that KLRA will proceed with an IPO on favorable terms
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-159765 |
| Document: 0001193125-26-159765-index-headers.html | 0001193125-26-159765 |
| Document: 0001193125-26-159765-index.html | 0001193125-26-159765 |
| Document: 0001193125-26-159765.txt | 0001193125-26-159765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access